GLPwatch
Ozempic for Chronic kidney disease
semaglutide · FDA-approved
Last updated 2026-05-28 15:46 UTCOzempic (semaglutide) is FDA-approved for chronic kidney disease. Research highlights its pharmacokinetics, safety profile, and role in managing cardiovascular-kidney-metabolic syndrome.
AI summary of the sources below.
| Drug | Ozempic (semaglutide) |
|---|---|
| Condition | Chronic kidney disease |
| Approval status | FDA-approved |
| Research papers | 50 |
Ozempic is FDA-approved for chronic kidney disease. See the current label on the Ozempic page.
Research on semaglutide for chronic kidney disease (50)
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- The Discovery and Development of Liraglutide and Semaglutide.
- Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
- Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
- Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.
- The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
- Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.
- Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.
- Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.
- Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.
- Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.
- Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo.
- Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.
- Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis.
- Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist.
- Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment.
- Semaglutide: First Global Approval.
- Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials.
- Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.
- Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.
- Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment.
- Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial.
- Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment.
- Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
- Clinical Pharmacokinetics of Semaglutide: A Systematic Review.